PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.
PDL BioPharma Announces First Quarter 2013 Financial Results
PDL BioPharma to Announce First Quarter 2013 Financial Results on May 9, 2013
PDL BioPharma Appoints Peter Garcia as Chief Financial Officer
PDL BioPharma Completes Structured Financing and Royalty Transaction with Avinger
PDL BioPharma Completes Regular Quarterly Dividend Payment